197results about How to "Good clinical effect" patented technology

The invention discloses a CAR-T transgene vector based on replication defective recombinant lentivirus. The CAR-T transgene vector comprises an original nuclear replicon pUCOri sequence, a resistance gene AmpR sequence containing ampicillin, a virus replicon SV40 Ori sequence, a lentivirus packaging cis element, ZsGreen1 green fluorescent protein, an IRES ribosome binding sequence, a human EF1 alpha promoter , a chimeric antigen receptor of second-generation CAR or third-generation CAR and a regulating element, wherein the original nuclear replicon pUCOri sequence is used for plasmid replication; the resistance gene AmpR sequence is used for massively proliferating target strains; the virus replicon SV40 Ori sequence is used for enhancing replication in eukaryocyte; the lentivirus packaging cis element is used for lentivirus packaging; the ZsGreen1 green fluorescent protein is used for expressing green fluorescent for eukaryocyte; the IRES ribosome binding sequence is used for jointly transcribing and expressing protein; the human EF1 alpha promoter is used for conducting eukaryotic transcription on antigen receptor genes; the chimeric antigen receptor is used for forming the second-generation CAR or the third-generation CAR integrating recognition, transfer and start; the regulating element is used for enhancing expression efficiency of transgenes and used after eWPRE-enhanced type woodchuck hepatitis b virus is transcribed. Besides, the invention further discloses a construction method and application of the vector. By means of the CAR-T transgene vector and the construction method and application of the vector, secretion of cell factors and an in vitro killing effect of CAR-T cells can be remarkably improved, and the clinical treatment effect is remarkable.

The invention discloses an anti-BCMA chimeric antigen receptor, an encoding gene, a recombinant expression vector and an establishing method and application of the anti-BCMA chimeric antigen receptor, the encoding gene and the recombinant expression vector. The receptor comprises a CD8 leader chimeric receptor signal peptide, a BCMA single-chain antibody heavy chain VH, an Optimal Linker C, a BCMA single-chain antibody light chain VL, a CD8 Hinge chimeric receptor hinge, a CD8 Transmembrane chimeric receptor transmembrane domain, a CD137 chimeric receptor co-stimulatory factor and a TCR chimeric receptor T cell activating domain which are sequentially connected in series. In addition, the invention further discloses the encoding gene and the recombinant expression vector of the anti-BCMA chimeric antigen receptor and the establishing method and application of the encoding gene and the recombinant expression vector. The secretion of cell factors and the cytotoxicity in vitro of CAR-T cells can be remarkably improved, and the clinical treatment effect is outstanding.

The invention provides a Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases which comprises the following raw material herbs (by weight portions): astragalus root 480-660, radix salvia miltiorrhiza 60-160, red peony root 60-160, rhizome of Sichuan lovage 60-160, Chinese angelica root 60-160, safflower 60-160, leech 40-90, ground beetle 40-90, peach kernel 60-160, artificial ox gallstone 10-40, antelope's horn 10-40, buthus martensi kirsch 50-140, polygala root 60-160, acorus gramineus soland 60-160 and medicinal adjuvant. The invention also provides the method for preparation and use of the composition.

The invention discloses an anti-CD20 chimeric antigen receptor, an encoding gene, a recombinant expression vector, a construction method of the recombinant expression vector and an application. The anti-CD20 chimeric antigen receptor comprises CD8 leader chimeric receptor signal peptide, CD20 VL, Optimal Linker C, a CD20 single-chain antibody heavy chain VH, a CD8 Hinge chimeric receptor hinge, a CD8 Transmembrane chimeric receptor transmembrane domain, a CD137 chimeric receptor co-stimulated factor and a TCR chimeric receptor T cell activating domain which are connected in series. Moreover, the invention discloses an encoding gene of the anti-CD20 chimeric antigen receptor, a recombinant expression vector, a construction method of the recombinant expression vector, and an application. Secretion of cell factors and an in-vitro killing effect of CAR-T cells are obviously improved, and the CAR-T cells have an outstanding clinical treatment effect.

The invention discloses an anti-EGFRvIII chimeric antigen receptor, an encoding gene, a recombinant expression vector, a construction method of the recombinant expression vector, and an application. The anti-EGFRvIII chimeric antigen receptor comprises CD8 leader chimeric receptor signal peptide, an EGFRvIII single-chain antibody light chain VL, Optimal Linker C, an EGFRvIII single-chain antibody heavy chain VH, a CD8 Hinge chimeric receptor hinge, a CD8 Transmembrane chimeric receptor transmembrane domain, a CD137 chimeric receptor co-stimulated factor and a TCR chimeric receptor T cell activating domain which are connected in series. Moreover, the invention discloses an encoding gene of the anti-EGFRvIII chimeric antigen receptor, a recombinant expression vector, a construction method of the recombinant expression vector, and an application. Secretion of cell factors and an in-vitro killing effect of CAR-T cells are obviously improved, and the CAR-T cells have an outstanding clinical treatment effect.

The invention discloses a CD 123-targeting replication-defective recombinant lentivirus CAR-T transgenic vector. The CD 123-targeting replication-defective recombinant lentivirus CAR-T transgenic vector comprises a prokaryotic replicor pUC Ori sequence used for plasmid duplication; an amicillin resistance gene AmpR sequence used for amplification of a large number of target strains; a virus replicor SV40 Ori sequence used for enhancing the replication in eukaryocytes; a lentivirus packaging cis element used for lentivirus packaging; ZsGreen 1 green fluorescent protein used for green fluorescence expression of eukaryocytes; an IRES ribosome binding sequence used for co-transcription and co-expression of protein; a human EF1 alpha promoter used for eukaryotic transcription of genes of a chimeric antigen acceptor; the chimeric antigen acceptor used for forming second-generation CAR or third-generation CAR integrating recognition, delivery and promoting; an eWPRE element used for enhancing the expression efficiency of transgenes. In addition, the invention further discloses a construction method and applications of the vector. With the vector, the secretion of the cell factors and the in-vitro lethal effect of the CAR-T cells can be obviously improved, and the effect in treatingacute myelogenous leukemia (AML) clinically is outstanding.

The invention discloses an anti-HER2 chimeric antigen receptor, an encoding gene, a recombinant expression vector, a construction method of the recombinant expression vector, and an application. The anti-HER2 chimeric antigen receptor comprises CD8 leader chimeric receptor signal peptide, an HER2 single-chain antibody heavy chain VH, Optimal Linker C, an HER2 single-chain antibody light chain VL, a CD8 Hinge chimeric receptor hinge, a CD8 Transmembrane chimeric receptor transmembrane domain, a CD137 chimeric receptor co-stimulated factor and a TCR chimeric receptor T cell activating domain which are connected in series. Moreover, the invention discloses an encoding gene of the anti-HER2 chimeric antigen receptor, a recombinant expression vector, a construction method of the recombinant expression vector, and an application. Secretion of cell factors and an in-vitro killing effect of CAR-T cells are obviously improved, and the CAR-T cells have an outstanding clinical treatment effect.

The invention discloses a CD22-taregted replication-defective recombinant lentivirus CAR-T transgenic vector. The vector comprises a prokaryotic replicon pUC Ori sequence for plasmid replication, an ampicillin-containing resistance gene AmpR sequence for mass amplification of a target strain, a virus replicon SV400ri sequence for enhancing replication within eukaryotic cells, a lentivirus packaging cis element for lentivirus packaging, ZsGreen1 green fluorescence protein for expression of green fluorescence of the eukaryotic cells, an IRES ribosome binding sequence for common transcriptional expression of the protein, a human EF1[alpha] promoter for eukaryotic transcription of a chimeric antigen receptor gene, a chimeric antigen receptor for constituting the second or the third generation of CAR integrating identification, transferring and promoting, and an eWPRE element for enhancing a transgenic expression efficiency. In addition, the invention also discloses a construction method and an application of the vector. The vector disclosed by the invention can significantly improve secretion of cell factors and an in vitro killing effect of CAR-T cells; and the vector is obvious in effect on the clinical treatment of precursor B-cell acute lymphocytic leukemia.

The invention discloses an anti-CD33 chimeric antigen receptor, a coding gene, a recombinant expression vector and a construction method and an application of the recombinant expression vector. The anti-CD33 chimeric antigen receptor comprises a CD8leader chimeric receptor signal peptide, a heavy chain VL of a CD33 single-chain antibody, an Optimal Linker C, a light chain VH of the CD33 single-chain antibody, a CD8Hinge chimeric receptor hinge, a CD8Transmembrane chimeric receptor transmembrane domain, a CD137 chimeric receptor co-stimulation factor and a TCR chimeric receptor T-cell activation domain, which are serially connected in sequence. In addition, the invention discloses the coding gene of the anti-CD33 chimeric antigen receptor, the recombinant expression vector and the construction method and the application of the recombinant expression vector. According to the anti-CD33 chimeric antigen receptor, the secretion of cell factors and the in vitro killing effect of CAR-T (Chimeric Antigen Receptor T-Cell Immunotherapy) cells can be remarkably improved, and the clinical treatment effect is outstanding.

The invention discloses a CD 30-targeting replication-defective recombinant lentivirus CAR-T transgenic vector. The CD 30-targeting replication-defective recombinant lentivirus CAR-T transgenic vector comprises a prokaryotic replicor pUC Ori sequence used for plasmid duplication; an ampicillin resistance gene AmpR sequence used for amplification of a large number of target strains; a virus replicor SV40 Ori sequence used for enhancing the replication in eukaryocytes; a lentivirus packaging cis element used for lentivirus packaging; ZsGreen 1 green fluorescent protein used for green fluorescence expression of the eukaryocytes; an IRES ribosome binding sequence used for co-transcription and co-expression of protein; a human EF1 alpha promoter used for eukaryotic transcription of genes of a chimeric antigen acceptor; the chimeric antigen acceptor used for forming second-generation CAR or third-generation CAR integrating recognition, delivery and promoting; and an eWPRE element used for enhancing the expression efficiency of transgenes. In addition, the invention further discloses a construction method and applications of the vector. With the vector, the secretion of the cell factors and the in-vitro lethal effect of the CAR-T cells can be obviously improved, and the effect in treating hodgkin lymphoma or non-hodgkin lymphoma clinically is outstanding.

The invention discloses a vascular stent. Multiple unit rings are arranged to form a tubular structure, wherein the unit rings comprise the first unit rings and the second unit rings, the area formed by each first unit ring in an enclosing mode is smaller than that formed by each second unit ring in an enclosing mode, and the first unit rings and the second unit rings are arranged in a spaced and staggered mode. The first unit rings and the second unit rings have a central point symmetry structure, the vascular stent presents a tubular stent after being unfolded, and included angles are axially formed between the first unit rings and the second unit rings and the tubular stent. According to the vascular stent, the net-shaped structure is formed by arranging the two kinds of unit rings with the different sizes in the spaced mode, high radial support force is achieved, and therefore the flexibility and the expansion property of the stent can be greatly enhanced; in addition, by designing the inclination angles of the two kinds of unit rings, the flexibility and the expansion property of the stent are further enhanced, and it is guaranteed that the force borne by the stent is effectively transmitted in the direction of a stent rod.

The invention relates to a preparation method of dandelion herb extract. The preparation method comprises the following steps: crushing dandelion herb, extracting via microwaves, extracting by using acetone, and purifying by using a chromatographic column. The preparation method comprises the following specific steps: cutting dandelion herb into small sections, crushing the dandelion herb sections, filtering the dandelion herb powder by virtue of a 30-mesh to 40-mesh sieve, and obtaining crude powder; adding 70 to 80 percent ethanol solution into dandelion herb crude powder, extracting for 50to 60 seconds in a microwave extraction instrument with microwave power of 500 to 600 w, and obtaining extract liquid; concentrating the extract liquid to obtain extract; extracting the extract for 3to 4 times by using the acetone, obtaining an acetone extraction solution, removing the solvent in a rotary steaming manner, and obtaining the extract; and separating purifying the extract in a columnchromatographic method, firstly washing, then continuously eluting by using an ethyl acetate elution solution, collecting eluted liquid, drying, and obtaining the dandelion herb extract, wherein thetotal content of luteolin, quercetin, chlorogenic acid and caffeic acid is greater than or equal to 70 percent. The preparation method of the dandelion herb extract is simple in process, easy in industrial production and high in content of active ingredients.

The invention provides a Chinese medicinal composition for treating heart failure. The composition includes the following herbal medicines in parts by weight: 65-185 parts of codonopsis pilosula, 65-185 parts of acanthopanax root, 65-185 parts of astragalus root, 65-185 parts of root of red-rooted salvia, 15-185 parts of turtle shell, 50-150 parts of tuckahoe, 30-130 parts of semen lepidii, 50-150 parts of dwarf lilyturf root, 30-130 parts of bitter orange and medicinal auxiliary materials. Meanwhile, the invention provides a preparation method of the Chinese medicinal composition for treating heart failure. The Chinese medicinal composition is used for treating the heart failure. The Chinese medicinal composition has the effects of overcoming the defects of the conventional formulations of medicinal broth and the like; by using a water extraction method, active ingredients with a clinical curative effect in the composition are remained; by using high-efficiency dynamic loop extraction equipment, the active ingredients are extracted to the greatest extent; and thus, the clinical curative effect of the composition is guaranteed, and the prevention and treatment effect of the composition on qi deficiency, blood stasis and water retention symptoms of the heart failure is obviously superior to those of similar medicaments.

The invention discloses a visual fusion functional trainer and a training method of the same, mainly used to rectify child strabismus and belonging to the ophthalmic medical apparatus technical field. The trainer comprises an outer casing component, a marker moving device, a head fixing device and a circuit control unit, wherein the head fixing device is arranged on the outer casing component to fix the head of a user; the marker moving device and the circuit control unit are arranged inside the outer casing component; a marker component on the marker moving device extends out of the outer casing component through an opening on the slipway on the outer casing component so as to be corresponding to the position of the head fixing device; and the circuit control unit is in electrical connection with the control end of the power-driven device of the marker moving device, thereby controlling the movement or the stop of the marker component on the marker moving device. The fusion functional trainer designed by the invention can realize quick and effective rectification of strabismus and trains the stereoscopic vision of a patient, thereby reaching the effect of improving eyesight.

The invention discloses an anti-CD138 chimeric antigen receptor, a coding gene, a recombinant expression vector and a construction method and an application of the recombinant expression vector. The anti-CD138 chimeric antigen receptor comprises a CD8leader chimeric receptor signal peptide, a light chain VH of the CD138 single-chain antibody, an Optimal Linker C, a heavy chain VL of a CD138 single-chain antibody, a CD8Hinge chimeric receptor hinge, a CD8Transmembrane chimeric receptor transmembrane domain, a CD137 chimeric receptor co-stimulation factor and a TCR chimeric receptor T-cell activation domain, which are serially connected in sequence. In addition, the invention discloses the coding gene of the anti-CD138 chimeric antigen receptor, the recombinant expression vector and the construction method and the application of the recombinant expression vector. According to the anti-CD138 chimeric antigen receptor, the secretion of cell factors and the in vitro killing effect of CAR-T (Chimeric Antigen Receptor T-Cell Immunotherapy) cells can be remarkably improved, and the clinical treatment effect is outstanding.

The invention discloses a Mesothelin-targeted replication-defective recombinant lentivirus CAR-T transgenic carrier which comprises a pronucleus replicon pUC Ori sequence for plasmid replication, an amicillin resistance gene AmpR containing sequence for mass amplification of target strain, virus replicon SV40Ori sequence for enhancing replication in eukaryocyte, a lentivirus packaging cis-element for lentivirus packaging, a ZsGreen1 green fluorescent protein for green fluorescence expression of eukaryocyte, an IRES ribosome combination sequence for joint transcriptional expression of protein, a human EF1(alpha) promoter for the eukaryotic transcription of chimeric antigen receptor gene, a chimeric antigen receptor for forming a second-generation CAR or third-generation CAR integrating identification, transfer and start, and an eWPRE element for improving the transgenic expression efficiency. Moreover, the invention also discloses an establishment method and application of the carrier. In the invention, the secretion of cell factors and the in-vitro killing effect of CAR-T cells can be remarkably enhanced, and the effect of clinical treatment of malignant pleural mesothelioma and pancreatic cancer is outstanding.

The invention discloses a compound acetylisovalery tylosin tartrate pellet. The compound acetylisovalery tylosin tartrate pellet is made by wrapping a drug-loading pellet core by adopting a coating material, wherein the drug-loading pellet core comprises the following components in percentage by weight: 1-30% of acetylisovalery tylosin tartrate, 1-30% of sulfadimidine, 5-20% of lactose, 5-25% of corncob powder, 10-60% of starch, 15-35% of microcrystalline cellulose and 0.5-12% of pelletizing binding agent; and weight of the coating material is not more than 8% of the total weight of the compound acetylisovalery tylosin tartrate pellet. The compound acetylisovalery tylosin tartrate pellet has a better clinical treatment effect, application amount of acetylisovalery tylosin tartrate can be reduced, and production cost can be saved; and drug release can be delayed, drug action time can be prolonged, and long-acting effect can be achieved, so that administration frequency is reduced and labour intensity can be alleviated.

The ointment for treating leukoplakia vulvae is prepared with medicine material, oil phase supplementary material and water phase supplementary material. The medicine material includes red sage, dittany bark, mint, borneol, vitamin AD, vitamin E, vitamin B2, metronidazole disodium phosphate, urea, dexamethasone and sexual hornmone. The oil phase supplementary material consists of stearic acid, Vaseline, Nipagin and glyceryl monostearte; and water phase supplementary material consists of glycerin, triethanolamine and lauryl sdsulfate. The ointment has total clinical effective rate up to 98%.

The invention discloses a traditional Chinese medicinal composition for treating blood stasis type postpartum abdominal pain and a preparation method thereof. The traditional Chinese medicinal composition comprises the following raw medicinal materials: angelica, donkey-hide gelatin, longan pulp, motherwort, caulis spatholobi, achyranthes, radix curcumae, safflower, cinnamon, cumin, galangal, cubeb, radix aucklandiae, litchi, rose, herba aristolochiae, spikenard, valeriana officinalis, cortex albiziae, vine of multiflower knotweed, jujube, radix astragali, Chinese yam and sea buckthorn. The traditional Chinese medicinal composition disclosed by the invention has the benefits of warming channel, activating blood circulation, removing stasis and relieving pain, is mainly used to treat the blood stasis type postpartum abdominal pain with short course of treatment and treat the disease based on syndrome differentiation from the overall situation to enable the efficacy to directly arrive at the focus, so as to achieve a better curative effect. The traditional Chinese medicinal composition is low in toxic and side effects, low in possibility of tolerance, simple and convenient in manufacturing technology, suitable in mouth feeling, easy to take by a patient, and low in cost.

The invention relates to a novel medicament for treating the cardio-cerebrovascular diseases and a preparation method and belongs to the technical field of preparation of the novel medicament for treating the cardio-cerebrovascular diseases. According to the invention, blood-sucking leeches, panax pseudoginseng and earthworm are used as raw materials. According to the invention, by a special preparation process of carrying out liquid nitrogen flash freezing, low-temperature superfine grinding and freeze drying before sterilization on the raw materials, the grinding fineness can reach 1 to 10 micrometers, the active ingredients of the blood-sucking leeches can be stored to the greatest extent, the active ingredients can be sufficiently adsorbed by a patient, and the novel medicament has comprehensive effects of promoting circulation, removing stasis, resisting to coagulation, reducing the pressure, lowering lipid, resisting to platelet aggregation and dissolving thrombi and is safe and reliable to take. The invention solves the problems that an existing medicament which uses leeches as the raw materials and is used for treating the cardio-cerebrovascular diseases adopts non blood-sucking leeches as the medicine and adopts a conventional grinding method, so that the antithrombase effect is poor and the curative effect is influenced; and enteric capsules only adopt the single medicine of blood-sucking leech and have poor effects of reducing the pressure, lowering the lipid and dissolving the thrombi and the preparation process ensures the active ingredients of the leeches not to be completely stored and is unbeneficial for a patient to adsorb the active ingredients.

The invention discloses sea eel compound feed and a preparation method thereof. The feed contains extruded soybeans, wheat, dried silkworm chrysalises, dried earthworms, plasma protein powder, bone meal, nano montmorillonite, propolis, corn oil, choline chloride, vitamin premix, microelement premix, a complex enzyme preparation and a traditional Chinese medicine additive. The preparation method comprises the following steps: a crushing step; a mixing step; a superfine crushing step; a granulating step; a spraying step. The sea eel compound feed has the beneficial effects that the feed contains the traditional Chinese medicine additive which has main treating principles of clearing away heat and toxic materials, cooling blood and stopping blooding; the theory of traditional Chinese medicine is taken as the basis and prevention and treatment are combined from the whole, so as to effectively dispel pathogenic factors and achieve a good clinic treatment effect; the traditional Chinese medicine additive is mutually matched with other raw materials so that the hemorrhagic opening diseases of sea eels can be treated and the capabilities of preventing and resisting the pathogenic factors of an organism are improved; the production performance of the sea eels can also be improved; the good health-care effect can be realized after consumers eat the sea eels; the economic benefits of producers are improved.

The invention discloses a traditional Chinese medicine preparation for treating oral mucosa lesions. The traditional Chinese medicine preparation consists of the following raw materials in parts by weight: 10-100 parts of scutellaria baicalensis, 8-80 parts of ligusticum wallichii, 8-80 parts of Angelica sinensis, 8-80 parts of jasmine, 5-60 parts of radix rehmanniae recen, 5-60 parts of semen plantaginis, 5-60 parts of radix curcumae, 5-60 parts of allium macrostemon, 3-30 parts of radix bupleuri, 3-30 parts of felwort and 3-30 parts of codonopsis pilosula. The invention further discloses a preparation method and an application of the traditional Chinese medicine preparation. The experiment proves that the traditional Chinese medicine preparation has good clinical treatment effects on patients suffering from oral mucosa lesions such as oral lichen planus and dental ulcer. The traditional Chinese medicine preparation disclosed by the invention is novel in formula and simple in composition, the price of each main drug is low, the administration cost is low, and the preparation method is easy to operate and controllable in quality and can be suitable for industrial production.

The invention discloses a covered stent. The covered stent comprises a skeleton and covering films, wherein the skeleton comprises a main body section and at least one branch section, the main body section is composed of a plurality of main body annular brackets which are arranged at intervals in sequence, and each branch section is composed of a plurality of branch annular brackets which are arranged at intervals in sequence; the covering films comprise a main body section covering film which is fixed in the circumferential direction of the main body section, and branch section covering films which are fixedly connected in the circumferential direction of the branch sections; at least the main body section covering film is provided with a folded covering film part, the folded covering film part is at least arranged between the adjacent main body annular brackets, and the folded covering film part is stretched or contracts in the axial direction when the covered stent is under the bent state. The invention provides the covered stent with the flexibility and bending degree being suitable for the neoplasia neck with various bending degrees.

The invention provides a traditional Chinese medicine composition for treating kidney diseases. The traditional Chinese medicine composition mainly comprises herba ephedrae, radix aconiti lateralis preparata, rhizoma zingiberis, roasted rhizoma atractylodis macrocephalae, poria and radix glycyrrhizae preparata. The traditional Chinese medicine composition has the advantages that the traditional Chinese medicine composition has functions of diffusing lungs, strengthening spleens and warming yang to promote diuresis; synergistic effects can be realized by various components in traditional Chinese medicines, accordingly, increase of extra burden on the kidneys of patients can be prevented, excellent clinical treatment effects can be realized by the traditional Chinese medicine composition, and the traditional Chinese medicine composition can become effective fast.

The invention provides a cefmenoxime hydrochloride / anhydrous sodium carbonate pharmaceutical composition liposome injection and a preparation method thereof. The cefmenoxime hydrochloride / anhydrous sodium carbonate pharmaceutical composition comprises the following components according to parts by weight: 1 part of cefmenoxime hydrochloride, 0.36-0.44 part of anhydrous sodium carbonate, 1-3 parts of liposome matrix and 0-1 part of additive. The prepared preparation has better stability and ensures medication safety.

The invention discloses a traditional Chinese medicine composition for treating systemic lupus erythematosus, which comprises the following components by weight: 12-30 parts of buffalo horns, 9-15 parts of radix rehmanniae, 10-30 parts of hedyotis diffusa, 5-15 parts of radix rhapontici, 6-12 parts of cortex moutan, 6-12 parts of red peony roots, 5-10 parts of mix-fried muscardine silkworm, 3-10 parts of radix gentianae macrophyllae, 6-15 parts of caulis sinomenii, 9-15 parts of processed rhizoma polygonati, 6-12 parts of stir-fried atractylodes, 3-9 parts of tangerine peel. The present invention also discloses a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition of the invention has the efficacy of clearing heat and removing toxic substances, cooling blood and dissipating stasis, nourishing yin, promoting body resistance and eliminating pathogenic factors, can relieve the symptoms of fever (with a body temperature of below 38 DEG C), skin lesions, arthralgia, alopecia, Raynaud's phenomenon, photosensitivity, irregular menstruation, xerostomia, night sweat, and the like for lupus erythematosus patients, and can restore results of blood routine examination and main immunological indexes.

The invention discloses a traditional Chinese medicine thread for treating sore and ulcer diseases and a preparation method thereof. The traditional Chinese medicine thread is formed by dipping and attaching the following raw materials in parts by weight on a medical thread: 8-4 parts of roots of lilac daphne, 5-1 part of brucea javanica kernel, 5-1 part of croton seed, 5-1 part of Uroctea charcoal, 5-1 part of charred schizonepeta and 8-4 parts of dragon's blood. When the traditional Chinese medicine thread is used in clinic, the acute and chronic stages of sore and ulcer diseases are effectively considered, and the traditional Chinese medicine thread has the composite treatment effects of removing necrotic tissues, detoxifying, expelling pus, stopping bleeding, astringing and promoting tissue regeneration.

The invention discloses a traditional Chinese medicine for treating bronchiectasia caused by phlegm-heat obstructing lung and a preparation method thereof. The traditional Chinese medicine comprises the following raw herbal materials: bulbus fritillariae cirrhosae, radix ophiopogonis, trichosanthes kirilowii maxim, scutellaria baicalensis, radices trichosanthis, arisaema cum bile, platycodon grandiflorum, concretio silicea bambusae, scaphium scaphigerum, concha meretricis seu cyclinae, fructus perillae, almond, aster, flos farfarae, folium mori, draba nemorosa, momordica grosvenori, thorny elaeagnus leaf, cortex lycii radicis, Chinese holly, calyx seu fructus physalis, Chinese olive, cordate houttuynia, sanicula lamelligera hance, adhatoda ventricosa, cudrania cochinchinensis, roughhaired holly root and ligularia rumicifolia. The traditional Chinese medicine has the beneficial effects that the traditional Chinese medicine has the efficacies of clearing heat and clearing the lung, and reducing phlegm and stopping coughing, is mainly used for treating bronchiectasia caused by phlegm-heat obstructing lung, is good in curative effect, short in treatment course, good in clinical treatment effect, small in toxic and side effects, simple in preparation process, easy to prepare, and low in cost, syndrome differentiation and treatment can be carried out from the whole body, the pharmacological effect is through to a focus of infection, and the drug tolerance is not easily generated.

The invention provides traditional Chinese medicine powder capable of effectively preventing and treating heat stress of broiler chickens for the poultry industry. The traditional Chinese medicine powder is characterized by consisting of the following components in parts by weight: 2-5 parts of honeysuckle, 1-3 parts of elsholtzia, 1-3 parts of cortex magnoliae officinalis, and 1-2 parts of forsythia. A preparation method of the traditional Chinese medicine powder comprises the following steps: grinding the four medicinal materials, uniformly mixing, and sieving, thus obtaining the traditional Chinese medicine powder. In the medicine provided by the invention, the honeysuckle has the efficacies of clearing away heat and toxic materials, and expelling wind and cold; the elsholtzia has the efficacies of inducing sweat and dispelling exogenous evils, removing dampness for regulating stomach, and inducing diuresis to alleviate edema; the cortex magnoliae officinalis has the efficacies of eliminating dampness and dissolving phlegm, removing stagnation and relieving fullness; and the polypharmacy has the efficacies of resolving summer heat, fever and polydipsia. The traditional Chinese medicine powder has a better clinical therapeutic effect on the prevention and treatment of heat stress of the broiler chickens.

The invention provides a traditional Chinese medicine composition for treating hyperuricemia and gouty arthritis, which comprises the following ingredients in parts by weight: 500-1500 parts of Smilax smilax, 300-900 parts of Mianzi, 100-500 parts of honeysuckle, 50-50 parts of vinegar Corydalis 250, Shanzi mushroom 50-150, and medicinal excipients. Provided is a preparation method of a traditional Chinese medicine composition for treating hyperuricemia and gouty arthritis of rheumatic stagnation-heat type, and is used for treating gout and hyperuricemia. The effect of the present invention is that the traditional Chinese medicine composition overcomes the disadvantages of traditional dosage forms such as decoction, adopts the method of water extraction, retains the active ingredients with clinical curative effect in the composition, and adopts high-efficiency dynamic circulation extraction equipment to extract effective ingredients, to ensure its clinical efficacy. The preventive and therapeutic effects on hyperuricemia and rheumatism-heat-type gouty arthritis are obviously better than similar drugs.